Hearing Loss- Pipeline Insight, 2024

Hearing Loss- Pipeline Insight, 2024

DelveInsight’s, “Hearing Loss- Pipeline Insight, 2024” report provides comprehensive insights about 35+ companies and 45+ pipeline drugs in Hearing Loss pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hearing Loss: Understanding

Hearing Loss: Overview

Hearing loss is an extremely common medical condition, progressing in incidence and severity with age. The affected population is also vast, varying between neonates to elderly patients, and is nearly omnipresent in the 70+ age group. Normal hearing function involves sound waves arriving at the auricle, passing through the external auditory canal (EAC), causing a vibration of the tympanic membrane. Vibration is then transmitted via the ossicles (malleus, incus, stapes) to the cochlea. Subsequently, hair cells inside the cochlea stimulate the eighth cranial nerve that transfers the stimuli to the brain. Processing of crude sounds occurs in the higher cortices of the brain, and this includes the comprehension of language. Hearing loss can be conductive, sensorineural, or mixed. Conductive hearing loss takes place with disruption of the transmission of the sound waves to the cochlea. The most common causes include abnormal formation of the auricle or helix, cerumen impaction, ear canal foreign bodies, otitis externa, dysfunction or fixation of the ossicular chain, and middle ear effusion. Cholesteatoma, a benign though locally destructive trapping of squamous debris arising from the tympanic membrane, as well as other benign or malignant tumors, can result in conductive hearing loss. Sensorineural hearing loss (SNHL) usually results from problematic transmission of the stimuli at or after the cochlea. This loss could be related to hair cell dysfunction or a disorder of the eighth nerve itself. The main difference between the two kinds of hearing loss, apart from the pathophysiological features, is that patients with conductive hearing loss perceive the sounds diminished, while SNHL patients may perceive the sounds diminished and distorted. Hearing loss that involves problematic transmission before and after the cochlea is called mixed hearing loss. There are multiple reasons for hearing impairment. In the pediatric population, genetic causes are the most common, accounting for more than 50% of hearing loss. Genetic causes involve various syndromes that have hearing loss as one of their features; however, there is an entire entity of non-syndromic genetic hearing loss, wherein patients suffer hearing loss while the rest of their function is normal. Mutations, autosomal differences, as well as unknown genetic diversity relate to this type of hearing loss. Hearing loss affects approximately 0.5 to 1% of children in the United States and can be profound, mild, or moderate. Management of conductive hearing loss focuses on the treatment of the underlying disease. Conservative methods such as removal of the foreign body, micro suction of the cerumen, or discharge in the ear canal are necessary if the ear canal is blocked. Complications of hearing loss in children involve speech delay and failure to thrive in school. Any child with speech delay requires a formal hearing evaluation, as this is the most common cause.

""Hearing Loss- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hearing Loss pipeline landscape is provided which includes the disease overview and Hearing Loss treatment guidelines. The assessment part of the report embraces, in depth Hearing Loss commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hearing Loss collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hearing Loss R&D. The therapies under development are focused on novel approaches to treat/improve Hearing Loss.

Hearing Loss Emerging Drugs Chapters

This segment of the Hearing Loss report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hearing Loss Emerging Drugs

• PIPE 505: Pipeline Therapeutics

PIPE-505 is a gamma secretase inhibitor that targets two pathways associated with sensorineural hearing loss and audibility. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Sensorineural Hearing Loss.

• FX 322: Frequency Therapeutics

FX-322 is designed to treat the underlying cause of sensorineural hearing loss (SNHL) by regenerating sensory hair cells through activation of progenitor cells already present in the cochlea. Frequency’s lead asset FX-322 has shown the first-ever statistically significant and clinically meaningful hearing improvement signal in clinical trials. Three clinical studies in which a single dose of FX-322 was administered have shown hearing improvements in measures of speech perception. In addition, in all FX-322 studies, this drug candidate was observed to be well-tolerated with no serious drug-related adverse effects. FX-322 is currently in Phase II b study.

• Arazasetron: Sensorion

Arazasetron (SENS-401), is a first-in-class drug candidate to treat Sudden Sensorineural Hearing Loss (SSNHL). It is aiming at treating or protecting against inner ear lesions that lead to nerve degeneration and sensory hair cell loss. It is protected by a solid intellectual property with two patent families.

Further product details are provided in the report……..

Hearing Loss: Therapeutic Assessment

This segment of the report provides insights about the different Hearing Loss drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Hearing Loss

There are approx. 35+ key companies which are developing the therapies for Hearing Loss. The companies which have their Hearing Loss drug candidates in the most advanced stage, i.e. phase II include, Frequency Therapeutics.

Phases

DelveInsight’s report covers around 45+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Hearing Loss pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hearing Loss: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hearing Loss therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hearing Loss drugs.

Hearing Loss Report Insights

• Hearing Loss Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hearing Loss Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hearing Loss drugs?
• How many Hearing Loss drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hearing Loss?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hearing Loss therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hearing Loss and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sensorion
• Frequency Therapeutics
• Pipeline Therapeutics
• GenVec
• Novartis
• Otonomy
• PTC Therapeutics
• Strekin
• Audion Therapeutics
• Sensorion
• Eisai Co Ltd
• Astellas Pharma
• Cell Mogrify
• Pfizer
• Decibel Therapeutics
• Sound Pharmaceuticals

Key Products

• PIPE 505
• FX 322
• Arazasetron
• CGF 166
• OTO 413
• Vatiquinone
• STR001-IT
• LY 3056480
• SENS-401
• Zonisamide
• Research programme: sensorineural hearing loss therapeutics
• Sirolimus
• DB OTO
• Research programme: regenerative hearing therapeutics